BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26100136)

  • 1. Naringenin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.
    Kim JH; Lee JK
    Arch Pharm Res; 2015 Nov; 38(11):2042-8. PubMed ID: 26100136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sesamolin enhances NK cell lysis activity by increasing the expression of NKG2D ligands on Burkitt's lymphoma cells.
    Kim JH; Lee JK
    Int Immunopharmacol; 2015 Oct; 28(2):977-84. PubMed ID: 26298637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
    Bae DS; Hwang YK; Lee JK
    Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in NKG2D ligand recognition and responses by NK cells.
    Le Bert N; Gasser S
    Immunol Cell Biol; 2014 Mar; 92(3):230-6. PubMed ID: 24445601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
    Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
    J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
    Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
    Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
    Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
    Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.
    Chang YH; Connolly J; Shimasaki N; Mimura K; Kono K; Campana D
    Cancer Res; 2013 Mar; 73(6):1777-86. PubMed ID: 23302231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
    Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
    Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
    Mei JZ; Guo KY; Wei HM; Song CY
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NKG2D-mediated natural killer cell cytotoxicity against myeloid leukemia cells OUN-1].
    Lu XZ; Cai XH; Ma LD; Chen BA
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):444-7. PubMed ID: 22967377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma.
    Belting L; Hömberg N; Przewoznik M; Brenner C; Riedel T; Flatley A; Polić B; Busch DH; Röcken M; Mocikat R
    Eur J Immunol; 2015 Sep; 45(9):2593-601. PubMed ID: 26151313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NKG2D receptor: sensing stressed cells.
    López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
    Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY; Mei JZ; Yao KT
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
    Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
    Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.
    Morgado S; Sanchez-Correa B; Casado JG; Duran E; Gayoso I; Labella F; Solana R; Tarazona R
    J Innate Immun; 2011; 3(4):365-73. PubMed ID: 21576932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.